These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11371997)

  • 1. Risks in new drug development: approval success rates for investigational drugs.
    Dimasi JA
    Clin Pharmacol Ther; 2001 May; 69(5):297-307. PubMed ID: 11371997
    [No Abstract]   [Full Text] [Related]  

  • 2. Trends in risks associated with new drug development: success rates for investigational drugs.
    DiMasi JA; Feldman L; Seckler A; Wilson A
    Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Market failure and the poverty of new drugs in maternal health.
    Fisk NM; Atun R
    PLoS Med; 2008 Jan; 5(1):e22. PubMed ID: 18215109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA Breakthrough-Drug Designation - Four Years of Experience.
    Darrow JJ; Avorn J; Kesselheim AS
    N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970
    [No Abstract]   [Full Text] [Related]  

  • 5. New drug development in the United States from 1963 to 1999.
    Dimasi JA
    Clin Pharmacol Ther; 2001 May; 69(5):286-96. PubMed ID: 11371996
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug pipeline: 3Q15.
    DeFrancesco L
    Nat Biotechnol; 2015 Nov; 33(11):1126. PubMed ID: 26544135
    [No Abstract]   [Full Text] [Related]  

  • 7. New estimates of drug development costs.
    Frank RG
    J Health Econ; 2003 Mar; 22(2):325-30. PubMed ID: 12606149
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical approval success rates for investigational cancer drugs.
    DiMasi JA; Reichert JM; Feldman L; Malins A
    Clin Pharmacol Ther; 2013 Sep; 94(3):329-35. PubMed ID: 23739536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obstacles and opportunities in new drug development.
    Kaitin KI
    Clin Pharmacol Ther; 2008 Feb; 83(2):210-2. PubMed ID: 18202685
    [No Abstract]   [Full Text] [Related]  

  • 10. The COPD Pipeline.
    Gross NJ
    COPD; 2009 Dec; 6(6):488-9. PubMed ID: 19938973
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical R&D performance by firm size: approval success rates and economic returns.
    DiMasi JA
    Am J Ther; 2014; 21(1):26-34. PubMed ID: 23344103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What does R&D really cost?
    Huff B
    GMHC Treat Issues; 2001; 15(7-8):1-7. PubMed ID: 11548507
    [No Abstract]   [Full Text] [Related]  

  • 13. Balancing US patent and FDA approval processes: strategically optimizing market exclusivity.
    Fernandez DS; Huie JT
    Drug Discov Today; 2004 Jun; 9(12):509-12. PubMed ID: 15183155
    [No Abstract]   [Full Text] [Related]  

  • 14. Returns to R&D on new drug introductions in the 1980s.
    Grabowski HG; Vernon JM
    J Health Econ; 1994 Dec; 13(4):383-406. PubMed ID: 10140531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs with breakthrough status charm investors.
    Senior M
    Nat Biotechnol; 2013 Nov; 31(11):945-7. PubMed ID: 24213748
    [No Abstract]   [Full Text] [Related]  

  • 16. Costing drug development.
    Nat Rev Drug Discov; 2003 Apr; 2(4):247. PubMed ID: 12680358
    [No Abstract]   [Full Text] [Related]  

  • 17. Rising research and development costs for new drugs in a cost containment environment.
    DiMasi JA
    Pharmacoeconomics; 1992; 1(Suppl 1):13-20. PubMed ID: 10146926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 19. Key factors in the rising cost of new drug discovery and development.
    Dickson M; Gagnon JP
    Nat Rev Drug Discov; 2004 May; 3(5):417-29. PubMed ID: 15136789
    [No Abstract]   [Full Text] [Related]  

  • 20. Market watch: Upcoming market catalysts in Q3 2016.
    Ranj T
    Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.